The study for acupoint stimulation on preventive treatment of advenocortical function inhibition induced by etomidate: a randomized, double-blind, prospective study.

Not Applicable

Not yet recruiting

• Conditions: advenocortical function inhibition

• Registration Number: ITMCTR2000004212
• Lead Sponsor: The Second Affiliated Hospital of Xi'an Jiaotong University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-02-20

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients must meet all of the following criteria for inclusion in this study:
1. Aged 18-90 years, gender unlimited;
2. ASA range from I to III grade;
3. 18 kg/m24. Clear understanding and voluntary participation in this study.

Exclusion Criteria

1. Patients with endocrine system diseases such as Kuxing syndrome, pituitary adenoma and adrenal tumor;
2. Patients with hormone drugs within 3 months before operation;
3. Patients with glucocorticoid drugs intraoperatively and postoperatively;
4. Asthma patients;
5. Severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory infection, acute attack of chronic obstructive pulmonary disease, uncontrolled asthma, active massive hemoptysis, severe pulmonary hypertension, etc);
6. Acute heart failure; unstable angina pectoris; myocardial infarction within 6 months before screening; resting electrocardiogram heart rate < 50 beats / min; third degree atrioventricular block; severe arrhythmia; moderate and severe valvular disease; QTc: male >= 450 ms, female >= 470ms; patients with aortic aneurysm;
7. Infectious heart diseases such as myocarditis or endocarditis; septicemia;
8. People with mental system diseases (schizophrenia, mania, bipolar disorder, insanity, etc.) and long-term history of taking psychotropic drugs and cognitive impairment;
9. Anemia or thrombocytopenia: Hb < 90g/L; PLT < 80x10^9/L;
10. Dysfunction of blood coagulation: PT > ULN +3s and/or APTT > ULN+10s;
11. Liver dysfunction: AST and/or ALT >= 2.5 x ULN, TBIL >= 1.5 x ULN;
12. Renal dysfunction: urea or urea nitrogen >= 1.5x ULN, serum creatinine greater than the upper limit of normal value;
13. There was a history of substance abuse, drug abuse and alcohol abuse within two years prior to the screening period, with alcohol consumption, i.e. drinking more than 2 units of alcohol per day on average (1 unit =360 ml beer or 45 ml liquor with 40% alcohol or 150 wine);
14. Patients who did not receive regular hypotension or have poor blood pressure control (sitting systolic blood pressure >= 160 mmHg or 90 mmHg, and / or 100 mmHg diastolic blood pressure during screening);
15. Patients whose blood glucose was not satisfactorily controlled (random blood glucose >= 11.1 mmol/l);
16. Allergic or contraindicated drugs such as benzodiazepines, opioids, etomidate, propofol and their components;
17. Patients identified as having difficulties in respiratory management (modified Mallampati ? grade);
18. Participated in any clinical drug trial and used the trial drug as a subject in the last 3 months;
19. Patients who could undergo adrenal surgery;
20. Contraindications of trauma and infection in acupuncture and moxibustion puncture site;
21. Other factors that may interfere with the results.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified